-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Accepts UroGen's UGN-103 Application for Bladder Cancer Treatment

PUBT·10/19/2026 12:03:21
Listen to the news
FDA Accepts UroGen's UGN-103 Application for Bladder Cancer Treatment
  • FDA accepted UroGen Pharma’s UGN-103 application to treat adults with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer.
  • The agency set a June 14, 2027, target action date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9847629) on October 19, 2026, and is solely responsible for the information contained therein.